Trump targets drug prices – 5 implications for pharma
On July 24, 2020, President Trump signed several executive orders directing the secretary of Health and Human Services (HHS) to take steps to lower...
Search for:
Accelerating – and maintaining – drug approvals in the U.S.
Bringing a drug to market is the ultimate milestone for any pharmaceutical firm that has invested significant effort, not to mention time and resources, into developing its product. But all that work and outlay does not stop at marketing approval—this achievement must be maintained. There can be various regulatory requirements that a firm must meet […]
‘Open for Innovation’ outlines post-Brexit path
As the UK prepares to embark on a new path outside of the EU, writes Virginia Acha in the preface to a new look at the British pharma industry, it will need the best policies in place to foster a priority on innovation. “Open for Innovation: UK Biopharma R&D Sourcebook 2016” underscores the need for […]
From ‘ad hoc’ to ‘visionary’: How your company’s competitive intelligence can get from here to there
In a poll conducted during a recent presentation on biopharma competitive intelligence (CI), Jamie Munro, global practice leader, portfolio & licensing at Clarivate Analytics, asked participants to rank their companies’ CI efforts on a scale of 1 to 5, with 1 representing “ad hoc,” a scrambling, reactive approach to industry events as they occur, and […]
Partnering priorities: Do your homework, tell your story
Companies use meetings like BIO CEO and BIO International as sounding boards for fine-tuning company strategy, weighing, for example, the wisdom of taking an asset all the way through to commercialization or teaming up with a strategic partner.
European biotech on course for record year with $3.9B raised in first half of 2018
This is the second of a two-part series on Life Sciences Connect looking at the current robust financial climate for biopharma. “Biopharma IPOs gone wild,” also via BioWorld, the daily biopharma news service from Clarivate Analytics, appeared on July 10, 2018. European biotechnology firms engaged in drug development raised $3,904 million during the first half […]
Alzheimer’s disease: One year later
Alzheimer’s disease (AD) affects more than 35 million people worldwide and is the sixth-leading cause of death in the US, where its care costs are predicted to rise from $200 billion in 2012 to $1.1 trillion by 2050. The disease is the only one of the top-ten leading causes of death in the US that […]
9 steps for modernizing your medtech account segmentation strategy
9 essential steps to modernizing your medtech account and stakeholder segmentation strategy Account segmentation and targeting used to be a pretty...
Get the insights you need to support coronavirus (COVID-19) research
Access the world’s leading research and late-breaking news on Coronavirus (COVID-19) with this collection of tools and resources from Clarivate Analytics.
Get the insights you need on the Coronaviruses from Clarivate Analytics
Access the world’s leading research and late-breaking news on this rapidly evolving health emergency. A global health emergency can occur without warning, as we are currently experiencing with the rapidly-spreading coronavirus outbreak. As scientists attempt to develop vaccines and treatments as quickly as possible to meet the increasing needs of those affected, medical researchers and […]